Is Invesco Biotechnology & Genome ETF (PBE) a Good Investment Right Now

The Invesco Biotechnology & Genome ETF (PBE) offers a unique investment opportunity in the healthcare sector

Is Invesco Biotechnology & Genome ETF (PBE) a Good Investment Right Now
Is Invesco Biotechnology & Genome ETF (PBE) a Good Investment Right Now

Austin: The Invesco Biotechnology & Genome ETF, or PBE, launched back in 2005. It’s designed to give investors broad exposure to the healthcare sector. This ETF is managed by Invesco and has gathered over $250 million in assets.

PBE aims to match the performance of the Dynamic Biotechnology & Genome Intellidex Index. This index looks at companies based on various criteria like price momentum and earnings momentum.

When it comes to costs, PBE has an annual operating expense of 0.58%, which is pretty standard for its category. The ETF also offers a modest dividend yield of 0.05%.

Most of PBE’s investments are in the healthcare sector, making up about 99.80% of its portfolio. The top holdings include companies like Natera Inc, Gilead Sciences, and Biogen, which together account for a significant portion of the fund.

So far this year, PBE has seen a gain of about 2.03%, and over the past year, it’s up roughly 3.55%. However, it’s worth noting that it has a beta of 0.79, indicating it carries a bit more risk compared to some other options.

If you’re considering alternatives, there are other ETFs like the SPDR S&P Biotech ETF and the iShares Biotechnology ETF that might catch your eye. These funds have larger asset bases and lower expense ratios, making them appealing for cost-conscious investors.

In summary, PBE is a solid choice for those looking to invest in the biotech and genome space, but it’s always good to compare with other options to find what fits your investment goals best.

Disclaimer: All images comply with fair use for educational and informational purposes. Sourced from public platforms. Have questions? Contact us.
Fact-Checking Policy: Accurate information is our focus. If errors are found, please let us know, and corrections will be made swiftly.